Erschienen in:
01.05.2012 | Letter to the Editor
Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia
verfasst von:
Ho-Young Yhim, Hee Sun Kim, Na-Ri Lee, Eun-Kee Song, Jae-Yong Kwak, Chang-Yeol Yim
Erschienen in:
International Journal of Hematology
|
Ausgabe 5/2012
Einloggen, um Zugang zu erhalten
Excerpt
Dasatinib has been approved for the treatment of Philadelphia chromosome (Ph)-positive malignancies such as acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) [
1‐
4]. Dasatinib had 325-fold greater potency than imatinib mesylate (IM) in cells transduced with unmutated
BCR-
ABL [
5]. Despite its favorable toxicity profile, adverse events associated with dasatinib include myelosuppression, pleural effusion, diarrhea, and liver enzyme abnormalities. Of these, bleeding has been reported in 26–40 % of patients with CML or Ph-positive ALL receiving dasatinib [
6,
7]. Most dasatinib-induced bleeding occurs in the gastrointestinal tract, whereas bleeding in the central nervous system is a rare event. …